First human test of LP-005 drug completed in healthy volunteers
NCT ID NCT06294301
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug, LP-005, in 68 healthy adults aged 18 to 50. The main goal was to check if the drug is safe and how the body handles it. This information will help design future studies for people with a rare blood disorder called PNH.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill tame a rare blood disease? early safety trial begins
- New drug pegcetacoplan tested in teens with rare blood disorder
- New PNH drug VSA012 enters early human testing
- New pill CMS-D017 enters first human safety trials
- Thousands with blood diseases to be tracked in massive chinese registry
- New drug SLN12140 aims to control PNH in early trial